ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO815

Low-Dose Iron Treatment and Erythropoiesis Efficiency in Hemodialysis Patients with Anemia Treated by Erythropoiesis-Stimulating Agents

Session Information

Category: Dialysis

  • 605 Dialysis: Anemia and Iron Metabolism


  • Kuji, Tadashi, Yokodai Central Clinic, Yokohama, Kanagawa, Japan
  • Suzuki, Shota, Yokohama City University, Yokohama, Kanagawa, Japan
  • Fujikawa, Tetsuya, Yokohama National University, Yokohama, Kanagawa, Japan

Anemia is a common comorbidity and is a major cause of morbidity and mortality among hemodialysis (HD) patients. Iron deficiency is a major cause of resistance to erythropoiesis-stimulating agents (ESA) therapy; however, excessive iron has toxic effects including oxidative stress. Even standard-dose parental iron supplementation causes oxidative stress due to free iron in the blood, therefore low-dose iron is desirable to reduce the free iron release for optimal prognosis. We aimed to investigate whether low-dose iron supplementation is as effective for erythropoiesis as standard-dose iron supplementation.


A randomized, controlled, parallel-group study was performed for six months. One hundred and two patients were randomized to receive 20mg intravenous elemental iron per week (Low-dose iron group: n = 53) or 40 mg intravenous elemental iron doses per week (Standard-dose iron group: n = 49). Ferritin and transferrin saturation were measured at two-month intervals. Iron was administered for two months when HD patients showed iron deficiency (transferrin saturation < 20% and ferritin < 100ng/ml). ESA resistance index was defined as the weekly weight-adjusted dose of ESA divided by hemoglobin concentration.


No significant differences in baseline characteristics except systolic blood pressure were evident between the two groups. The mean numbers of two-month long iron supplementation were 0.74 ± 0.83 in low-dose iron group and 0.49 ± 0.56 in standard-dose iron group. Mean Hb levels during the evaluation period of 6 months were 10.5 ± 0.4 g/dL in the low-dose iron group and 10.4 ± 0.4 g/dL in the standard-dose iron group (p = 0.315). There was a tendency toward low ESA dose in the low-dose iron group compared to the standard-dose iron group (4116.1 ± 2170.4 IU/week vs. 4935.1 ± 1792.8 IU/week, p = 0.079). There was a trend towards decrease in ferritin levels in low-dose iron group compared with the standard-dose iron group (-36.4±50.5 ng/mL vs. -11.8 ± 65.2 ng/mL, p = 0.073). Reticulocyte hemoglobin levels (newly synthesized hemoglobin) and ESA resistance index were not significantly different between the two groups.


Low-dose iron treatment suppresses ferritin levels, but does not decrease hemoglobin levels and reticulocyte hemoglobin levels or does not increase required ESA dose.